ANCA-Associated Vasculitis: An Update

被引:93
|
作者
Almaani, Salem [1 ]
Fussner, Lynn A. [2 ]
Brodsky, Sergey [3 ]
Meara, Alexa S. [4 ]
Jayne, David [5 ]
机构
[1] Ohio State Univ, Div Nephrol, Wexner Med Ctr, Columbus, OH 43201 USA
[2] Ohio State Univ, Div Pulm & Crit Care Med, Wexner Med Ctr, Columbus, OH 43201 USA
[3] Ohio State Univ, Dept Pathol, Wexner Med Ctr, Columbus, OH 43201 USA
[4] Ohio State Univ, Div Rheumatol, Wexner Med Ctr, Columbus, OH 43201 USA
[5] Univ Cambridge, Dept Med, Cambridge CB2 0QQ, England
关键词
ANCA vasculitis; review; vasculitis; crescentic glomerulonephritis; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; DAILY ORAL CYCLOPHOSPHAMIDE; CHURG-STRAUSS-SYNDROME; WEGENERS-GRANULOMATOSIS; MICROSCOPIC POLYANGIITIS; PLASMA-EXCHANGE; MAINTENANCE THERAPY; RANDOMIZED-TRIAL; RISK-FACTORS; REMISSION-MAINTENANCE;
D O I
10.3390/jcm10071446
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue inflammation, often associated with the production of antibodies that target neutrophil antigens. The two major antigens targeted by ANCAs are leukocyte proteinase 3 (PR3) and myeloperoxidase (MPO). AAV can be classified into 3 categories based on patterns of clinical involvement: namely, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA). Clinically, AAV involves many organ systems including the lungs, kidneys, skin, and nervous system. The prognosis of AAV has improved dramatically due to advances in the understanding of its pathogenesis and treatment modalities. This review will highlight some of the recent updates in our understanding of the pathogenesis, clinical manifestations, and treatment options in patients with AAV focusing on kidney involvement.
引用
收藏
页数:22
相关论文
共 50 条
  • [31] Current Therapies for ANCA-Associated Vasculitis
    Lally, Lindsay
    Spiera, Robert
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 227 - 240
  • [32] Update on treatment of ANCA-associated vasculitis
    Holle, Julia U.
    Moosig, Frank
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2024, 83 (10): : 787 - 799
  • [33] Metabolic syndrome in ANCA-associated vasculitis
    Smits, Daniela R. Petermann
    Wilde, Benjamin
    Adegani, Makan Kianersi
    de Jongh, Heiko
    van Paassen, Pieter
    Tervaert, Jan Willem Cohen
    RHEUMATOLOGY, 2013, 52 (01) : 197 - 203
  • [34] Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis
    Marzano, Angelo Valerio
    Raimondo, Maria Gabriella
    Berti, Emilio
    Meroni, Pier Luigi
    Ingegnoli, Francesca
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2017, 53 (03) : 428 - 438
  • [35] Evolution of Therapy for ANCA-Associated Vasculitis with Kidney Involvement
    Rajasekaran, Arun
    Rizk, Dana V.
    KIDNEY360, 2023, 4 (12): : 1794 - 1805
  • [36] Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice
    Chevet, Baptiste
    Cornec, Divi
    Casal Moura, Marta
    Cornec-Le Gall, Emilie
    Fervenza, Fernando C.
    Warrington, Kenneth J.
    Specks, Ulrich
    Berti, Alvise
    RHEUMATOLOGY, 2023, 62 (05) : 1787 - 1803
  • [37] Autoantibodies in ANCA-associated Vasculitis
    Wiik, Allan S.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2010, 36 (03) : 479 - +
  • [38] The Future of ANCA-associated Vasculitis
    Holle, Julia U.
    Wieczorek, Stefan
    Gross, Wolfgang L.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2010, 36 (03) : 609 - +
  • [39] ANCA-associated vasculitis (AAV)
    Aries, P. M.
    Schneeweis, C.
    KARDIOLOGE, 2009, 3 (04): : 339 - 348
  • [40] Biomarkers in ANCA-Associated Vasculitis
    Lally, Lindsay
    Spiera, Robert F.
    CURRENT RHEUMATOLOGY REPORTS, 2013, 15 (10)